All true, but a big name banger would probably want to underwrite another secondary offering in order to prvide coverage, and I don't think AMPE wants to dilute any further.
A Breakthrough/Fast Track designation by the FDA would be a major event, and that could happen in the next month.
...seems to be the motto for the trading in AMPE. Still a pathetically small market cap for a company with a likely blockbuster drug hitting the market in a year or so.
Be careful what you wish for, the better the news gets, the lower the stock price goes. Train wreck right now.
...great news and the stock is down today. In fact, down 6 days in a row now. Sad.
Nice info, except I believe the company feels that approval would come in the 1st Quarter of 2015, and that's without any special designation.
...my understanding is that the company is applying for this in the next month, and the FDA will respond positively or negatively within 2 weeks. If they are approved for such, it would be huge plus for the share price. If they are not, it is a non event since there is very litle expectation that this could occur, and I doubt that there would be a press release regarding any denial.
Good info, arbtrdr. My guess is that once results are in from the final Ampion trial, the company will then strike a deal with Big Pharma for either an outright sale or a partnership. If results mirror the Spring Trial, and there's no reason to expect they won't, then FDA approval is a given. The only question is time frame.
A sale would bring in a big short term payday like you mentioned, but a partnership would lead to the greatest potential appreciation in the stock price. Either way, there are lots of Pharma companies that are currently interested in AMPE.
I think the Aegis report is clearly dated and somewhat irrelevant now. In light of the very positive Ampion trial results, and the fact that they now intend to manufacture the drug themselves to start with, a $12.00 target is obsolete. The margins on manufacturing Ampion are expected to be huge(according to the company). My guess is that there are multiple large Pharma companies knocking on their door. But given that they intend to manufacture the drug themselves initially, any partnership deal won't happen until they get manufacturing in place & there is clarification as to FDA approval of Ampion. Then AMPE will be negotiating from a very strong position in any Pharma partnership deal. A $2 Billion market cap($50.00/share) is within reach and a reasonable valuation in the next few years.
..almost all of the risk has been taken out of the stock with the extremely positive Ampion Spring Trial results, which were a homerun. As I've said before, Optina would merely be icing on the cake in regards to the potential of Ampion. What is there negative to write about now? Now we wait for what kind of decision the FDA makes in regards to AMPE's application for a Biologic License for Ampion. I feel very good that they will get some kind of fast track/accelerated approval.
...well spoken. I feel confident that AMPE will get some form of fast track/accelerated approval decision from the FDA. A $2 Billion+ market cap is an achievable goal, and that would put us near $50.00/share. A higher yet market cap is not a pipe dream either. As I've stated before, Ampion could be considered a "miracle drug" in time.
..as a trader, you can take profits. As an investor, this thing is going many multiples higher over the next year or so. Ampion will be a blockbuster, and potentially mega blockbuster, drug.
what is he going to write about? Ampion results were so good that Optina & Zertane are now a sideshow to the story of AMPE. Adam "The Perp" Fraudstein is a pimp for the shorts, who are going to have a religious experience trying to cover their misplaced bets.